These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Ruff CT; Giugliano RP; Antman EM Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881 [TBL] [Abstract][Full Text] [Related]
4. [Antidote treatment during use of direct anticoagulants]. Rutherford OW; König MSS; Risnes K; Raouf N; Atar D; Ghanima W Tidsskr Nor Laegeforen; 2018 Feb; 138(3):. PubMed ID: 29411596 [No Abstract] [Full Text] [Related]
5. [Treatment with inhibitors of new oral direct anticoagulants in patients with severe bleedings or urgent surgical procedures. The new dabigatran antidote: the place of idarucizumab in clinical practice]. Boda Z Orv Hetil; 2016 Mar; 157(12):443-50. PubMed ID: 26971644 [TBL] [Abstract][Full Text] [Related]
6. Coordinating emergent procedures after andexanet alfa. Culbreth SE; Sylvester KW; Rimsans J; Connors JM Am J Hematol; 2019 Oct; 94(10):E278-E282. PubMed ID: 31342554 [No Abstract] [Full Text] [Related]
7. [NOAC: Real-life data and the role of antidotes for the treatment of bleeding]. Darius H Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):99-104. PubMed ID: 28144725 [TBL] [Abstract][Full Text] [Related]
8. Management of direct oral anticoagulants-associated bleeding in the trauma patient. von Heymann C; Rosenthal C; Kaufner L; Sander M Curr Opin Anaesthesiol; 2016 Apr; 29(2):220-8. PubMed ID: 26934279 [TBL] [Abstract][Full Text] [Related]
9. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. Huisman MV; Fanikos J Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438 [TBL] [Abstract][Full Text] [Related]
10. [Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks]. Dülgeroglu J; Schmidt D Praxis (Bern 1994); 2018 Apr; 107(9-10):485-493. PubMed ID: 29690851 [No Abstract] [Full Text] [Related]
11. [State of the art: Direct oral anticoagulants and transfusion]. Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500 [TBL] [Abstract][Full Text] [Related]
12. Security profile of direct anticoagulants. Preferred use in atrial fibrillation. Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA; Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323 [TBL] [Abstract][Full Text] [Related]
13. Clinical implications of reversal agents for direct oral anticoagulants. Monagle S; Eikelboom JW; Ng KH; Bhagirath VC Future Cardiol; 2017 Mar; 13(2):153-159. PubMed ID: 28198201 [TBL] [Abstract][Full Text] [Related]
14. Reversal of anticoagulants: an overview of current developments. Greinacher A; Thiele T; Selleng K Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311 [TBL] [Abstract][Full Text] [Related]
15. Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update. Cappellari M; Bovi P Thromb Haemost; 2015 Aug; 114(2):440-4. PubMed ID: 25809649 [No Abstract] [Full Text] [Related]
16. [Monitoring options and reversal agents for oral anticoagulants]. Thorup SB; Husted SE; Vang ML Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568 [TBL] [Abstract][Full Text] [Related]
17. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044 [TBL] [Abstract][Full Text] [Related]
18. [New oral anticoagulants in patients with atrial fibrillation in a urban health center]. Rodríguez Pérez L; Capilla Lozano F; Gallego Fuentes R; Buitrago F Med Clin (Barc); 2016 Mar; 146(6):280-1. PubMed ID: 26343157 [No Abstract] [Full Text] [Related]
19. Andexxa--an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther; 2018 Jun; 60(1549):99-101. PubMed ID: 29913471 [No Abstract] [Full Text] [Related]